RNS Number : 1335Z
Oxford Biomedica PLC
15 July 2008
FOR IMMEDIATE RELEASE 15 JULY 2008
OXFORD BIOMEDICA REPORTS FURTHER DATA FROM INTERIM REVIEW OF TROVAX® PHASE III TRIST
STUDY
Oxford, UK - 15 July 2008: Oxford BioMedica (LSE: OXB), announced that it has written to
all investigators participating in the TRIST
study summarising the background to the independent Data Safety Monitoring Board's recent
recommendations. The letter also summarises the
study procedures to continue the follow up of all patients enrolled into the study.
This letter has been made publically available on the Company's web site at
http://www.oxfordbiomedica.co.uk/pdfs/investigators.pdf
Oxford BioMedica is grateful to all investigators participating in TRIST for their
continued support of this important ongoing study.
-Ends-
For further information, please contact:
Oxford BioMedica plc:
Mike McDonald, Chief Executive Officer Tel: +44 (0)1865 783 000
Nick Woolf, Chief Business Officer
JPMorgan Cazenove Limited:
James Mitford/ Gina Gibson Tel: +44 (0)20 7588 2828
City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Tel: +44 (0)20 7466 5000
Johnson Buchanan Communications
Scientific/Trade Press Enquiries:
Holly Griffiths/ Katja Stout/ Claire Mosley Tel: +44 (0)20 7457 2020
College Hill Life Sciences
US Enquiries:
Thomas Fechtner Tel: (646) 378 2900
The Trout Group LLC
Notes to editors
1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer
immunotherapy and gene-based therapies. The Company
was established in 1995, as a spin-out from Oxford University, and is listed on the London
Stock Exchange.
The Company has a platform of gene delivery technologies, which are based on highly
engineered viral systems. Oxford BioMedica also has
in-house clinical, regulatory and manufacturing know-how. TroVax® is the Company's
therapeutic vaccine, which is in clinical development for
multiple solid cancers. The product is licensed to sanofi-aventis for global development and
commercialisation. Oxford BioMedica has three
other products in clinical development, including ProSavin®, a novel gene-based treatment for
Parkinson's disease, in a Phase I/II trial.The Company is underpinned by over 80 patent families, which represent one of the broadest
patent estates in the field. The Company has a
staff of approximately 85. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth,
Sigma-Aldrich, MolMed and Virxsys. Technology
licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is
available at www.oxfordbiomedica.co.uk
2. TroVax®
TroVax is Oxford BioMedica's novel therapeutic cancer vaccine, which is being developed in
collaboration with sanofi-aventis. It is
designed specifically to stimulate an anti-cancer immune response and has potential
application in most solid tumour types. TroVax targets
the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours.The presence of 5T4 is correlated with poor
prognosis. The product consists of a Modified Vaccinia Ankara vector, which delivers the gene
for 5T4 and stimulates a patient's body to
produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the
5T4 antigen.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGUUBUMUPRGAA
|